Anti-HIV activity of a novel aminoglycoside-arginine conjugate.
We have previously described conjugates of L-arginine with aminoglycosides (AAC) that have shown anti-human immunodeficiency virus type 1 (HIV-1) activity in in vitro cell culture systems. Here, we extend our report to a novel neomycin B-arginine conjugate (NeoR) that has shown up to 30-fold increased potency over previous AAC compounds. NeoR inhibited the replication of both R5 and X4 strains of HIV-1 in cells expressing the appropriate coreceptor or peripheral blood mononuclear cells. In lymphoid tissue ex vivo, NeoR blocked the replication of the dualtropic strain 89.6 suggesting anti-HIV activity of AAC on the site of in vivo virus replication. NeoR blocked the binding of HIV particles to lymphoid cells and was also able to antagonize the activity of the CXCR4 receptor so it may prevent the emergence of X4 HIV-1 strains. Nevertheless, in a cellular assay, we were unable to detect anti-Tat dependent transactivation activity as previously suggested for this family of compounds.
Cabrera
Cecilia
C
Retrovirology Laboratory, Fundació irsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, 08916, Badalona, Spain.
Gutiérrez
Arantxa
A
Barretina
Jordi
J
Blanco
Julià
J
Litovchick
Alexander
A
Lapidot
Aviva
A
Clotet
Bonaventura
B
Esté
José A
JA
D019380:Anti-HIV Agents / Q000494:pharmacology*; D002460:Cell Line; D046508:Culture Techniques; D005601:Framycetin / Q000031:analogs & derivatives / Q000494:pharmacology*; D015658:HIV Infections / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D014066:Palatine Tonsil / Q000187:drug effects; D019718:Receptors, CXCR4 / Q000378:metabolism; D014779:Virus Replication / Q000187:drug effects
D019380:Anti-HIV Agents; D019718:Receptors, CXCR4; C444521:neomycin B-arginine conjugate NeoR; D005601:Framycetin